Webinar recording - Accelerating Pain Therapeutic Discovery: Nav1.9 as a Drug Target for Treatment of Pain

In this on-demand webinar, experts discuss the crucial role of voltage-gated sodium channels, particularly NaV1.9, in pain mechanisms, and how innovative technologies are unlocking new opportunities for non-opioid pain therapies.

Complete the form below to watch the presentations.

  • The Voltage-Gated Sodium Channel NaV1.9 a Selective Target for Analgesic Drug Discovery (Associate Professor David Bulmer PhD, Group Leader University Associate Professor, University of Cambridge)
  • Development of a High-throughput Automated Electrophysiology Assay for NaV1.9 (Dr Eddy Stevens, CSO, Metrion).

Recommended Publications
Latest Publications
Early In Vitro Preclinical Cardiovascular Safety Assessment for Smarter Drug Discovery

Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.

Development of a High-Throughput Automated Electrophysiology Assay for Human Nav1.9 Inhibitor Screening

Alex Haworth, Senior Scientist at Metrion, introduces a poster demonstrating Metrion's development of a monoclonal CHO cell line expressing hNav1.9, validated via manual and automated patch clamp techniques.

View All
Early In Vitro Preclinical Cardiovascular Safety Assessment for Smarter Drug Discovery
Evaluation of hNav1.9 Screening Cascade for Analgesic Drug Discovery
View All
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
Copyright © 2024 Metrion. All rights reserved | Privacy notice | Registered as a company in England and Wales: 09669815 | VAT: GB 219828479
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram